Add BrightSurf on Google Email

Study solves mystery of genetic-test results for patient with suspected heart condition

Researchers have developed a technique to determine the significance of gene variants of uncertain significance in patients with suspected heart conditions. By using advanced genetic-editing tools and stem cell technology, they were able to confirm that a patient had a mild case of long QT syndrome and rule out another condition.

SourceStanford Medicine·JournalJournal of the American College of Cardiology·DateJun 26, 2018

New link found between alcohol, genes and heart failure

Researchers have discovered a genetic link between alcohol consumption and heart failure, specifically in individuals with a faulty titin gene. The study found that even moderate amounts of alcohol intake can worsen the condition by reducing heart output in patients with dilated cardiomyopathy caused by the faulty gene.

SourceImperial College London·JournalJournal of the American College of Cardiology·DateMay 25, 2018

New diagnostic technique picks up the S in vision

A new diagnostic technique has been successfully tested at the University of Bradford, allowing for the isolation of responses from S-cone photoreceptors. This breakthrough could help in the diagnosis of diseases such as Types 1 and 2 diabetes, glaucoma, and high blood pressure.

SourceUniversity of Bradford·JournalJournal of the Optical Society of America·DateMay 1, 2018

Expert panel issues new guidelines for lung cancer molecular testing

The new guidelines update the 2013 recommendations to include genetic alterations driving lung cancer and new drugs to target these alterations. Testing for ROS1 in all cases of lung adenocarcinoma is now recommended, as well as using circulating tumor DNA and cytology specimens when tissue is unavailable.

SourceUniversity of Colorado Anschutz Medical Campus·JournalArchives of Pathology & Laboratory Medicine·DateJan 30, 2018

The Down syndrome 'super genome'

A study by UNIGE and UNIL researchers found that individuals with Down syndrome have an excellent genome, better than the average genome of people without the genetic abnormality. This high-quality genome may compensate for the disabilities caused by the extra chromosome 21, enabling some fetuses to reach full term and grow up to old age.

SourceUniversité de Genève·JournalGenome Research·DateJan 19, 2018

Accessing your own genomic data is a civil right but requires strategies to manage safety

The Genetic Information Nondiscrimination Act (GINA) created an individual access right to genomic data, but its implementation has been marred by controversy and conflicting regulations. Bioethicists and safety regulators have raised concerns about the misuse of genetic data, while lawmakers argue that GINA solves a non-existent problem.

SourceCell Press·JournalAmerican Journal of Human Genetics·DateJan 4, 2018

Precision medicine test may help detect coronary artery disease

A blood-based precision medicine test incorporating age, sex, and gene expression score (ASGES) helped evaluate older outpatients with symptoms of obstructive coronary artery disease. The study found higher incidence of major adverse cardiovascular events in those with high ASGES scores compared to low ASGES scores

SourceWiley·JournalJournal of the American Geriatrics Society·DateDec 6, 2017

Barley no longer an afterthought in beer flavor

Researchers at Oregon State University found notable differences in the taste of beers malted from two barley varieties, revealing novel flavors that carry through malting and brewing into beer. The study's results have significant implications for the brewing industry, particularly for beer connoisseurs.

SourceOregon State University·JournalJournal of the American Society of Brewing Chemists·DateNov 27, 2017

The benefits & dangers when genetic testing companies partner with orphan drug developers

The partnership between genetic testing companies and orphan drug developers has both positive and negative implications. On the one hand, it can lead to faster diagnosis and treatment of rare diseases. However, there are also concerns over patient privacy and potential price-gouging due to rising healthcare costs.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalGenetic Testing and Molecular Biomarkers·DateSep 27, 2017